SLC2A1 and Dravet syndrome: A series of uncontrolled trials also found cognitive improvements during KD treatment for obesity, HIV-associated neurocognitive impairment, and Dravet Syndrome (DS) [100,101,102,103]; however, no change or worsening was reported for patients with Glut1-DS or pediatric refractory epilepsy [104,105,106].